In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Serono Focuses On China For Expansion

This article was originally published in PharmAsia News

Executive Summary

Merck Group's Chairman of the Executive Board Karl-Ludwig Kley declared that the company will expand its investment in China and other Asian countries in the near future. China has been one of Merck's top 10 markets for antitumor drug Erbitux (cetuximab), with sales growing over 70 percent this year. However, the company thinks there is still potential for greater performance. Merck's pharmaceutical business in 2007 hit €4.88 billion, of which Serono's prescription drugs contributed €4.46 billion. Serono concentrates on oncology, neurodegenerative disease, autoimmune and inflammatory disease, as well as infertility and endocrine disease. Merck hopes that Serono will become one of the top 15 pharmaceutical companies in China before 2012. (Click here for more - Chinese Language)



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts